

## **Director Shareholdings**

### **Synairgen plc (“Synairgen” or the “Company”)**

The Company was informed on 7 November 2006 that Dr David Bruce Campbell, Non-executive Director of Synairgen and Executive Director and Chief Scientific Officer of IP Group plc, acquired a beneficial interest in 216,923 ordinary shares of 1p each in the Company (“Ordinary Shares”) on 7 November 2006. This beneficial interest results from the transfer of Ordinary Shares from IP Group plc to Dr David Bruce Campbell for nil consideration as part of the IP Group plc bonus scheme. As a consequence his holding in the Company equates to 216,923 Ordinary Shares, which represents approximately 1.00 per cent. of the issued ordinary share capital of the Company.